Nanorods show benefits cancer treatment

Researchers at the Georgia Institute of Technology and the University of California, San Francisco, have found an even more effective and safer way to detect and kill cancer cells. By changing the shapes of gold nanospheres into cylindrical gold nanorods, they can detect malignant tumors hidden deeper under the skin, like breast cancer, and selectively destroy them with lasers only half as powerful as before – without harming the healthy cells. The method, which allows for a safer, deeper penetrating noninvasive cancer treatment, has just appeared in the Journal of the American Chemical Society.

Last year, the father and son research team of Mostafa El-Sayed and Ivan El-Sayed, showed that gold nanoparticles coated with a cancer antibody were very effective at binding to tumor cells. When bound to the gold, the cancer cells scattered light, making it very easy to identify the noncancerous cells from the malignant ones. The nanoparticles also absorbed the laser light more easily, so that the coated malignant cells only required half the laser energy to be killed compared to the benign cells. This makes it relatively easy to ensure that only the malignant cells are being destroyed.

Now, they've discovered that by changing the spheres into rods, they can lower the frequency to which the nanoparticles respond from the visible light spectrum used by the nanospheres to the near-infrared spectrum. Since these lasers can penetrate deeper under the skin than lasers in the visible spectrum, they can reach tumors that are inaccessible to visible lasers.

"With the nanospheres we're using visible lasers, but most of the solid cancer is under the tissues and visible light doesn't go but a few millimeters deep. But by using the nanorods we can tune them to react to the infrared lasers, which can penetrate the tumor without being absorbed by the tissues," said Mostafa El-Sayed, director of the Laser Dyanamics Laboratory and Regents' professor of chemistry at Georgia Tech.

Many cancer cells have a protein, known as Epidermal Growth Factor Receptor (EFGR), all over their surface, while healthy cells typically do not express the protein as strongly. By conjugating, or binding, the gold nanorods to an antibody for EFGR, suitably named anti-EFGR, researchers were able to get the nanoparticles to attach themselves to the cancer cells.

In this latest study, researchers incubated two malignant oral epithelial cell lines and one benign epithelial cell lines with nanorods conjugated to anti-EFGR. Not only were the malignant lines clearly identifiable as such under a simple optical microscope, but after being exposed to a continuous sapphire laser in the near infrared spectrum, the malignant lines only required half the laser energy to kill them as the healthy cells.

"This makes it more practical than the sphere in terms of treating cancer," said Mostafa El-Sayed. "For laser phototherapy treatment of skin cancer or, for diagnostic biopsies, the spheres are fine, but for phototherapy of cancer deep under the skin, like breast cancer, then one really needs to use the nanorods treatment."

Source: Georgia Institute of Technology

Related stories:

Scientists discover new link in pathway to cancer: hope for drug design
(PhysOrg.com) -- University of Manchester scientists have identified an exciting connection between a cell’s extracellular environment and the activity of a signalling pathway molecule that controls the development of organs and tissues, as well as cancer and kidney disease.
Drugs to inhibit blood vessel growth show promise in rat model of deadly brain tumor
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.


Experiments could lead to new treatments for neuroblastoma
Neuroblastoma is one of the most devastating diagnoses a child can receive. The cancer's victims average 2 years old when the disease is detected, most often by a parent feeling a lump in a child's abdomen. By then, the disease has often reached an advanced stage, and advanced neuroblastoma kills more than 50 percent of the children in whom it develops, despite aggressive treatment with surgery, chemotherapy and radiation.
Scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off. The findings shed light on the processes that lead to the development of autoimmunity and could also have implications for the development of drugs to increase the immune response in diseases such as cancer and HIV. The study paper appears online today in the journal Nature.
Cancer cells with a long breath: seeking the origin of brain tumors in children
Medulloblastoma is one of the most common and most malignant brain tumours among children and teenagers. These tumours grow very rapidly, and fifty percent of patients in the long term die from the condition. The details of the processes that lead to the growth of these tumours have remained unknown until now.
Key to Treating Cancer May Be Finding its Original Cell
(PhysOrg.com) -- Cancer biologists are turning their attention to the normal cells that give rise to cancers, to learn more about how tumor growth might be stopped at the earliest opportunity.
Researchers demonstrate activity of mebendazole in metastatic melanoma
Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
Checking more lymph nodes linked to cancer patient survival
Why do patients with gastric or pancreatic cancer live longer when they are treated at cancer centers or high-volume hospitals than patients treated at low-volume or community hospitals?

News discussion:

Nanotechnology news